Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Retained Earnings: 2019-2024

Historic Retained Earnings for Keros Therapeutics (KROS) over the last 6 years, with Dec 2024 value amounting to -$568.8 million.

  • Keros Therapeutics' Retained Earnings rose 12.33% to -$458.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$458.3 million, marking a year-over-year increase of 12.33%. This contributed to the annual value of -$568.8 million for FY2024, which is 49.12% down from last year.
  • Keros Therapeutics' Retained Earnings amounted to -$568.8 million in FY2024, which was down 49.12% from -$381.4 million recorded in FY2023.
  • Keros Therapeutics' Retained Earnings' 5-year high stood at -$65.0 million during FY2020, with a 5-year trough of -$568.8 million in FY2024.
  • Moreover, its 3-year median value for Retained Earnings was -$381.4 million (2023), whereas its average is -$392.9 million.
  • Data for Keros Therapeutics' Retained Earnings shows a maximum YoY slumped of 230.84% (in 2020) over the last 5 years.
  • Keros Therapeutics' Retained Earnings (Yearly) stood at -$65.0 million in 2020, then slumped by 90.36% to -$123.8 million in 2021, then slumped by 84.59% to -$228.4 million in 2022, then plummeted by 66.97% to -$381.4 million in 2023, then tumbled by 49.12% to -$568.8 million in 2024.